Wegovy and Cardiovascular Protection: What SELECT Means for 2026 Patients
By Dr. Sarah Mitchell, Respiratory Equipment Specialist & Wellness Editor · Published 2026-08-14 · 8 min read
Semaglutide 2.4 mg now carries an FDA indication to reduce major adverse cardiovascular events — independent of weight loss. What this means for prescribing.
The Trial That Changed Prescribing
SELECT randomized 17,604 adults with overweight/obesity and established cardiovascular disease. Semaglutide 2.4 mg reduced MACE by 20% versus placebo — independent of weight lost.
2026 Prescribing Reality
- Medicare Part D now covers Wegovy for the CV indication in eligible patients.
- Commercial payers follow, though prior authorization remains common.
- Many cardiologists now co-prescribe GLP-1s alongside statins and SGLT2 inhibitors.
---
Round Out Your Home Health Setup
Pair the latest wellness protocols with clinical-grade monitoring. Browse portable oxygen concentrators, CPAP machines, and respiratory accessories — or call our respiratory therapists at (877) 699-4365 for a free consult.